1. Medtech Insight
  2. >>Archive

Humana in $5.5 billion merger with United Healthcare

Humana, one of the largest publicly-traded managed care companies in the US, is to merge with United Healthcare in a $5.5 billion deal to create a $27 billion company operating across the entire US as well as Hong Kong, Singapore and South Africa. The new business will employ 55,000 people and becomes by far the largest managed care organisation in the US.

Humana, one of the largest publicly-traded managed care companies in the US, is to merge with United Healthcare in a $5.5 billion deal to create a $27 billion company operating across the entire US as well as Hong Kong, Singapore and South Africa. The new business will employ 55,000 people and becomes by far the largest managed care organisation in the US.

The companies claim to have identified savings in operating costs of between 3% and 5%, with medical cost reductions of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.